A Phase I/II Study of HKI-272 in Combination With Paclitaxel in Subjects With Advanced Solid Tumors and Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 09 Dec 2017
At a glance
- Drugs Neratinib (Primary) ; Paclitaxel
- Indications Breast cancer; Male breast cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Puma Biotechnology
- 09 Dec 2017 Results (n=966) of pooled subgroup analysis of NCT00445458, NCT00706030, NCT00398567, NCT00915018, NCT00741260 and NCT00300781trials assessing safety and efficacy of neratinib therapy in Asian patients from China, Hong Kong, Japan, Korea, Malaysia, Singapore, and Taiwan presented at the 40th Annual San Antonio Breast Cancer Symposium
- 14 May 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017, as reported by ClinicalTrials.gov.
- 17 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.